



RA & INFLAMMATION PRESCRIPTION REFERRAL FORM

NEW PATIENT CURRENT PATIENT

151 Cochituate Rd | Framingham, MA 01701
PHONE: 508-202-9993 | FAX: 508-202-9343 | 844-7-MYVCARE

Patient Name _____ D.O.B _____ Weight _____ Male Female
 Address _____ City _____ State _____ Zip _____
 Daytime Telephone _____ Evening Telephone _____ Cell _____ Email _____
 Ship to patient at Home Work **OR** Patient will pick up at Physician Office V-Care Pharmacy Date Needed _____
 ICD-10 Diagnosis _____ PPD (TB Test) _____ Chest X-Ray _____ Date of Labs _____
 Rheumatoid Factor Positive Total Swollen Joints _____ Previously treated Yes No If yes, which drugs: _____

Insured's Name _____ Relation to Patient _____ Eligible for Medicare Yes No If yes, Medicare # _____
 Prescription Card Yes No If yes, Carrier _____ Tel _____ Fax _____ Policy/Group# _____
 BIN# _____ PCN# _____ RXID# _____ RX Group# _____

Prescriber's Name _____ Office Contact _____
 Street Address _____ Suite # _____ City _____ State _____ Zip _____
 Tel _____ Fax _____ Email _____
 License # _____ NPI# _____ UPIN# _____ DEA# _____

PRESCRIPTION	Please attach copies of patient's insurance cards
<p>OLUMIANT (baricitinib) SIG: <input type="checkbox"/> 2 mg PO once daily with or without food QTY: 30 Refills: _____</p> <p>XELJANZ® <input type="checkbox"/> 5 mg tablet XELJANZ XR® <input type="checkbox"/> 11 mg tablet Rheumatoid Arthritis <input type="checkbox"/> 5 mg twice daily <input type="checkbox"/> 11 mg once daily Psoriatic Arthritis <input type="checkbox"/> 5 mg twice daily, used in combination with nonbiologic DMARDs <input type="checkbox"/> 11 mg once daily, used in combination with nonbiologic DMARDs Other _____ QTY: _____ Refills: _____</p> <p>KEVZARA® (arilumab) <input type="checkbox"/> 200 mg/1.14 mL single dose PFS <input type="checkbox"/> 150 mg/1.14 mL single dose PFS Dispense: <input type="checkbox"/> Inject 150 mg subcutaneously once every two weeks QTY: 2 Refills: _____ <input type="checkbox"/> Inject 200 mg subcutaneously once every two weeks QTY: 2 Refills: _____</p> <p>RASUVO Autoinjector Dose: <input type="checkbox"/> 7.5 mg <input type="checkbox"/> 10 mg <input type="checkbox"/> 12.5 mg <input type="checkbox"/> 15 mg <input type="checkbox"/> 17.5 mg <input type="checkbox"/> 20 mg <input type="checkbox"/> 22.5 mg <input type="checkbox"/> 25 mg <input type="checkbox"/> 27.5 mg <input type="checkbox"/> 30 mg SIG <input type="checkbox"/> Inject _____ mg subcutaneously every week QTY: 4</p> <p>HUMIRA® (adalimumab) Patient Weight (kg) _____ Dose: <input type="checkbox"/> 40 mg/0.8mL PFS <input type="checkbox"/> 40 mg/0.8mL Pens <input type="checkbox"/> 20 mg/0.4mL PFS Dispense: <input type="checkbox"/> Inject 40 mg subcutaneously every other week Juvenile Arthritis <input type="checkbox"/> Patient weight 15kg to < 30kg inject 20mg subcutaneously every other week QTY: _____ Refills: _____ <input type="checkbox"/> Patient weight > 30kg inject 40mg subcutaneously every other week QTY: _____ Refills: _____</p>	<p>SIMPONI® (golimumab) <input type="checkbox"/> Inject 50mg subcutaneously once per month Dose: <input type="checkbox"/> Sureject™ 50 mg/0.5mL <input type="checkbox"/> Prefilled Syringe 50 mg/0.5 mL QTY: _____ Refills: _____ SIMPONI ARIA® <input type="checkbox"/> 50 mg/4 mL (12.5 mg/mL) in a single use vial QTY: _____ Refills: _____ SIG: 2 mg/kg intravenous infusion over 30 minutes at weeks 0 an d 4, then every 8 weeks</p> <p>SIMPONI® Pen (#1 pen) <input type="checkbox"/> Inject 20mcg SQ Daily Refills: _____ KINERET® (anakinra) <input type="checkbox"/> Inject _____ mg subcutaneously every day QTY: _____ Refills: _____ ORENCIA® <input type="checkbox"/> Inject 125 mg subcutaneously weekly QTY: _____ Refills: _____ <input type="checkbox"/> 250 mg Vial (IV use only) Loading Dose: 10 mg/kg IV x 1 dose, then 125 mg SC weekly, start within 24hrs of IV dose, 1 dose, 4 week supply</p> <p>CIMZIA® (certolizumab pegol) <input type="checkbox"/> Initial Dose: 400 mg (two 200mg subcutaneous injections) at weeks 0, 2 & 4 (Starter Kit #6) QTY: 1 Kit <input type="checkbox"/> Maintenance Dose: 200mg subcutaneous injection every other week QTY: 28 Day Supply <input type="checkbox"/> Other _____ Refills _____</p> <p>ACTEMRA® (tocilizumab) Prefilled-Syringe QTY: _____ Refills: _____ <input type="checkbox"/> Inject 162mg subcutaneously every other week (pt wt <100kg) <input type="checkbox"/> Inject 162mg subcutaneously every week (pt wt >100kg or per clinical response) ACTEMRA IV _____ mg Q4W (every 4 weeks) Adult (IV) Dosage QTY: _____ Refills: _____ starting dose is 4 mg/kg every 4 wks followed by an increase to 8 mg/kg every 4 weeks based on clinical response</p> <p>ENBREL® <input type="checkbox"/> 50 mg <input type="checkbox"/> 25 mg <input type="checkbox"/> SureClick™ <input type="checkbox"/> PFS <input type="checkbox"/> MultiUse Vial <input type="checkbox"/> Enbrel Mini™/AutoTouch Dispense/Sig: <input type="checkbox"/> 1 x week <input type="checkbox"/> 2 x week <input type="checkbox"/> QTY: 28 Day Supply Refills: _____</p>

This is **not** a valid prescription and is intended for reference only. For providers: **Please send a valid prescription electronically or via fax.**

Prescriber's Signature (no stamps) _____ Date _____

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.